v3.26.1
LOSS PER SHARE (Schedule of Outstanding Shares of Common Stock Equivalents were Excluded from the Calculation due to their Antidilutive Nature) (Details) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total shares excluded 15,530,950 12,800,865 14,948,781 13,030,843
Stock-based awards [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total shares excluded 5,711,603 1,749,516 5,129,434 1,970,715
Notes 2025 [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total shares excluded 0 1,232,002 0 1,240,781
Notes 2029 [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total shares excluded [1] 9,819,347 9,819,347 9,819,347 9,819,347
[1] In conjunction with the issuance of the Notes 2029, in June 2024, the Company used approximately $25,230 of the net proceeds from this offering to pay the cost of the capped call transactions. In July 2024, following an additional issuance of the Notes 2029, $3,111 of net proceeds were used to pay the cost of capped call transactions. In accordance with ASC 260 "Earnings Per Share", antidilutive contracts, such as purchased call options, are excluded from the computation of diluted net income (loss) per share. Accordingly, any potential impact resulting from the capped call transaction is excluded from the Company's computation of diluted net income (loss) per share.